Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Lirilumab |
| Trade Name | |
| Synonyms | IPH-2102|BMS-986015|IPH 2102|IPH2102 |
| Drug Descriptions |
Lirilumab (IPH2102) is a monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), which leads to increased NK cell-mediated cytotoxicity towards tumor cells (PMID: 24326534). |
| DrugClasses | |
| CAS Registry Number | 1000676-41-4 |
| NCIT ID | C103820 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Epacadostat + Lirilumab + Nivolumab | Epacadostat Lirilumab Nivolumab | 0 | 1 |
| Lirilumab | Lirilumab | 0 | 2 |
| Lirilumab + Nivolumab | Lirilumab Nivolumab | 0 | 6 |